The interplay between genetics, the microbiome, DNA-methylation & gene-expression

Bonder, Marc Jan

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):
Bonder, M. J. (2017). The interplay between genetics, the microbiome, DNA-methylation & geneexpression. [Groningen]: University of Groningen.

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

Download date: 29-01-2020
The gut microbiome contributes to a substantial proportion of the variation in blood lipids

Circulation Research, DOI: 10.1161/CIRCRESAHA.115.306807

Jingyuan Fu¹,², Marc Jan Bonder², Maria C. Cenit², Ettje Tigchelaar²,³, Astrid Maatman², Jackie A.M. Dekens²,³, Eelke Brandsma¹, Joanna Marczynska²,⁴, Floris Imhann⁵, Rinse K. Weersma⁵, Lude Franke², Tiffany W. Poon⁶, Ramnik J. Xavier⁶,⁷,⁸, Dirk Gevers⁶, Marten H. Hofker¹,*, Cisca Wijmenga²,*, Alexandra Zhernakova²,³,*
Abstract

Rationale: Evidence suggests the gut microbiome is involved in the development of cardiovascular disease (CVD), with the host-microbe interaction regulating immune and metabolic pathways. However, there was no firm evidence for associations between microbiota and metabolic risk factors for CVD from large-scale studies in humans. In particular, there was no strong evidence for association between CVD and aberrant blood lipid levels.

Objectives: To identify intestinal bacteria taxa, whose proportions correlate with body mass index (BMI) and lipid levels, and to determine whether lipid variance can be explained by microbiota relative to age, gender and host genetics.

Methods and Results: We studied 893 subjects from the LifeLines-DEEP population cohort. After correcting for age and gender, we identified 34 bacterial taxa associated to BMI and blood lipids; most are novel associations. Cross-validation analysis revealed that microbiota explain 4.5% of the variance in BMI, 6% in triglycerides, and 4% in high-density lipoproteins (HDL), independent of age, gender and genetic risk factors. A novel risk model including the gut microbiome explained up to 25.9% of HDL variance, significantly outperforming the risk model without microbiome. Strikingly, the microbiome had little effect on low-density lipoproteins or total cholesterol.

Conclusions: Our studies suggest that the gut microbiome may play an important role in the variation in BMI and blood lipid levels, independent of age, gender and host genetics. Our findings support the potential of therapies altering the gut microbiome to control body mass, triglycerides and HDL.

1. University of Groningen, University Medical Center Groningen, Department of Pediatrics, Groningen, the Netherlands; 2. University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, the Netherlands; 3. Top Institute Food and Nutrition, Wageningen, the Netherlands; 4. Department of Immunology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland; 5. University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, the Netherlands; 6. Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA; 7. Gastrointestinal Unit and Center for the Study of Inflammatory Bowel Disease, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; 8. Center for Computational and Integrative Biology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA; *These authors jointly directed this study; Correspondence to: Dr. Jingyuan Fu, E-mail: fjingyuan@gmail.com
Introduction

In recent years, the gut microbiome has emerged as an important player in human health.\textsuperscript{1,2} Gut microbiota comprise thousands of microbial species that are involved in host metabolism by regulating energy extraction, activation of the immune system, drug metabolism and other processes.\textsuperscript{3,4} Association of bacterial composition to many diseases has been observed, including immune, inflammatory and metabolic phenotypes.\textsuperscript{5–7} Several mechanisms for the downstream effect of microbiota were discovered that also suggest they play a role in cardiovascular disease (CVD). The microbiota play an important role in choline diet-induced trimethylamine N-oxide (TMAO) production, which has been implicated in CVD.\textsuperscript{8} A further mouse study has demonstrated that atherosclerosis susceptibility can be transmitted via gut microbiota transplantation.\textsuperscript{9} Further, dysbiosis in the gut has been shown to induce increased permeability of the intestine, leading to increased systemic levels of bacterial products causing low-grade chronic inflammation.\textsuperscript{10} This inflammation may directly affect atherogenesis and has also been hypothesized to lead to the development of insulin resistance with concomitant effects on plasma lipids.\textsuperscript{11} Gut microbiota have also been linked with lipid metabolism through their role in bile acid metabolism. They can also influence the efficiency of energy harvest from ingested food\textsuperscript{12,13} and play a crucial role in the metabolic processes and development of obesity.

In line with these observations, altering the gut microbiome in humans and mice has shown improvement in metabolic syndrome.\textsuperscript{14–16} However, the evidence for a causal relationship between the gut microbiome and the development of CVD has not been firmly established for lack of large-scale human studies. Atherosclerosis, a lipid-driven disease, is the main underlying cause of CVD. However, to date, no studies of sufficient size have been done to assess the association between lipids and microbiota. In this study, we performed a systematic analysis of host genome, gut microbiome, body mass index (BMI) and blood lipids

---

**Novelty and Significance**

**What Is Known?**

- The human gut holds about 100 trillion bacteria, which together can weigh several pounds.
- This ecosystem (the microbiome) is shaped by early life events, the host genome, diet and other lifestyle factors.
- This bacterial community is associated with an individual’s susceptibility to many diseases, including cardiovascular diseases.

**What New Information Does This Article Contribute?**

- Healthy lipid levels are associated with increased microbial diversity.
- Body mass index (BMI) and blood lipids are associated with 34 different microbial taxonomies.
- A risk model including age, gender, genetic factors and gut microbiome explains a large part of the variation seen in BMI, triglycerides and high-density lipoprotein cholesterol.

The bacterial community in the human gut (known as the microbiome) has been referred to as an extra organ, or the second human genome, because of its important role in an individual’s health. As most of these bacteria cannot be cultured, we knew very little about their diversity and function until the recent development of innovative DNA sequencing technology. In our study we defined the microbial composition found in 893 human subjects by sequencing bacteria-specific 16s rRNA genes; we observed a large inter-individual variation in gut bacteria composition. We show that the bacterial diversity is associated with the lipid blood levels at human population level, especially with the levels of triglycerides and high-density lipoprotein cholesterol, and we report significant associations for 34 bacteria taxonomies. Our findings suggest microbial-intervention therapy will have the potential to help control blood lipid levels and prevent disease.
in 893 human subjects from the Dutch LifeLines-DEEP cohort. We investigated which gut bacteria were associated with BMI and blood lipids, and how much of the variation in blood lipids could be explained by the gut microbiome, relative to age, gender, body mass index and host genetics.

Results

Microbial Diversity in the LifeLines-DEEP Cohort

After quality control, our study included 893 human subjects. The study cohort had a wide range of age, BMI and blood lipids levels (Table 1). We assessed how variable the gut microbial composition was in the cohort in terms of microbial richness and diversity. The microbial richness reflects the number of OTUs per individual. The cohort had on average 238 OTUs per individual, ranging from 44 to 355. When individuals were grouped into different bins based on their richness, we observed that age and the proportion of females were higher in the richer OTU groups (Figure 1). The Spearman correlation showed the richness was significantly higher in women (P=0.0055) and increased with age (P=5.87x10\(^{-12}\)) (Online Table I). Given the abundance of OTUs, we computed the microbial diversity (Shannon's diversity index) and observed similar significant correlations for age and gender (Online Table I). We then investigated whether bacterial richness and diversity were correlated with BMI and lipid levels. After correcting for age and gender, OTU richness was negatively correlated with BMI (P=3.8x10\(^{-4}\)) and TG (P=1.37x10\(^{-4}\)), but positively correlated with HDL (P=8.3x10\(^{-4}\)). We did not observe significant correlations between microbial richness and LDL or TC levels (Online Table I).

Table 1. Summary of physical characteristics of 893 LifeLines-DEEP subjects

<table>
<thead>
<tr>
<th></th>
<th>Mean±s.d.</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Men n=380</td>
<td>Women n=513</td>
</tr>
<tr>
<td>Age in years</td>
<td>44.7±12.9</td>
<td>44.6±12.9</td>
</tr>
<tr>
<td>BMI</td>
<td>25.4±3.3</td>
<td>25.1±4.6</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.35±0.32</td>
<td>1.69±0.43</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>3.36±0.89</td>
<td>3.07±0.93</td>
</tr>
<tr>
<td>TC (mmol/L)</td>
<td>5.13±1.00</td>
<td>5.04±1.01</td>
</tr>
<tr>
<td>TG (mmol/L)</td>
<td>1.39±1.23</td>
<td>0.97±0.53</td>
</tr>
<tr>
<td>Log2-TG</td>
<td>0.20±0.81</td>
<td>-0.21±0.67</td>
</tr>
</tbody>
</table>
Association of Bacteria to Lipid Metabolites

We next tested for association between the individual bacterial OTU, BMI and blood lipid levels. After adjusting for age and gender, we identified 148 associated OTUs at FDR=0.05: 66 OTUs were associated with BMI, 114 with TG, and 34 with HDL (Online Tables II-IV). We did not detect any significant association at OTU level for LDL or TC. Of the 148 associated OTUs, 12 were shared by all three traits (BMI, TG and HDL); 29 OTUs were shared by BMI and TG and 4 by BMI and HDL, while 21, 64 and 9 OTUs were specifically associated with BMI, TG and HDL, respectively (Online Figure II). At the taxonomic level, we identified 50 significant associations for 34 unique taxonomies at FDR=0.05: 22 were associated with BMI, 23 with TG, 4 with HDL, and 1 with LDL (Figure 2, Online Table V). We found 18 associations (36%) were detected by binary analysis (presence/absence); 4 associations (8%) were detected by the quantitative model; and 28 associations (56%) were detected by the meta-analysis of binary and quantitative analyses (Online Table V). Although most of the associated taxonomies were shared across lipid metabolites and BMI, several microbes were predominantly linked to lipids rather than BMI. For example, the family *Clostridiaceae/Lachnospiraceae* (*N*16 in Figure 2), was specially associated with LDL (P=9.1x10^-5) (Online Table V), and not detected for BMI, nor other lipids. Further, the family *Pasteurellaceae* (*N*32) (Proteobacteria), genus Coprococcus (*N*24) (*Firmicutes*) and genus Collinsella species Stercoris (*N*2) showed strong association to TG levels (P=6.2x10^-5, P=4.6x10^-5 and P=0.0006, respectively), a nominal significance to other lipids, and no association to BMI (P>0.1).

We confirmed several previously described bacterial associations to obesity. An increased abundance of genus *Akkermansia* (*N*34) has been associated with a decrease in BMI (P=0.0005)18. We also confirmed the association of both the family *Christensenellaceae* (phylum *Firmicutes*) (*N*16) and the phylum *Tenericutes* (mainly represented by order RF-39) (*N*33) with low BMI (P=9.8x10^-7 and P=0.0002, respectively), as reported in the TwinsUK cohort.19 In addition, we identified a novel and strong association of these particular bacteria with lower levels of TG (P=2.1x10^-8 and P=2.7x10^-7, respectively), and higher levels of HDL (P=0.0047 and P=0.0006, respectively). We also observed several new associations with BMI and levels of TG and HDL, such as genus Eggerthella (*N*3) with increased TG (P=4.1x10^-9) and decreased HDL (P=6.3x10^-5), and family *Pasteurellaceae* (*N*32) with decreased TG (P=6.2x10^-5). The genus *Butyricimonas* (*N*9) was previously linked to a lean phenotype in mice after fecal transplantation from twins discordant for obesity.15 Our study shows that this genus is strongly associated with decreased TG (P=4.7x10^-6) and nominally associated with BMI and HDL in humans.
To anticipate how much BMI and blood lipids can be modulated by the gut microbiome, it is important to estimate what proportion of variation in these metabolic traits can be explained by the microbiome. To do so, we performed a 100x cross-validation analysis by splitting the dataset randomly into an 80% discovery set and a 20% validation set. The OTUs identified at P=1x10^{-5} level in the discovery set explained 2.74% variation in BMI in the validation set, 3.83% in TG, 2.46% in HDL, 0.01% variation in LDL, and 0.01% in TC. When the association significance decreased and the risk model included more (but less-significant) OTUs, the explained variation increased to 4.57% in BMI, 6.0% in TG, 4.0% in HDL, but was only 1.5% in LDL and 0.7% in TC (Figure 3A). To test the robustness of our estimation, we re-rarefied the OTU library 100 times and repeated the whole analysis. This approach yielded similar results, thereby confirming the robustness of our estimation (Online Figure III).

Microbiota Contribute Significantly to Lipid Variation, Independently of Age, Gender and Genetics

Evidence has already shown that the gut microbiome can be shaped by host genetics. We further tested whether the explained variation in the gut microbiome was independent of genetic factors by testing the association between the gut microbiome and genetic risk scores. To date, 157 genetic loci have been reported to be associated with blood lipid levels and 97 loci have been associated with BMI. In our cohort, these SNPs collectively explained 2.1% variation in BMI (P=1.66x10^{-5}), 3.4% in TG (P=3.22x10^{-8}), 7.5% in HDL (P<2.2x10^{-16}), 4.6% in LDL (P=8.0x10^{-11}), and 5.6% in TC (P=7.7x10^{-13}), after correcting for age and gender. However, we did not observe any significant association between the microbiome and the genetic risk at FDR=0.05. Nor did we find a significant association for either single SNPs (Online Table VI) or for the combined lipid and BMI genetic risk scores (Online Table VII). Our results indicated that the proportion of variation in BMI and lipid levels explained by the gut microbiome was different from that explained by genetic variation. Therefore, we further assessed whether
the microbiome could make a significant contribution to the explained variation beyond age, gender and genetic factors. Our analysis unambiguously showed that age, gender, genetics and the gut microbiome collectively explained 11.3% of the variation in BMI, 17.1% in TG and 25.9% in HDL-cholesterol, with the microbiome making a significant contribution to the explained variation in BMI (P=4.1x10^{-3}), TG (P=4.5x10^{-4}) and HDL (P=2.7x10^{-3}) (Figure 3B).

When we included BMI as a risk factor, the total explained variation in lipids increased to 25% in TG, 37.4% in HDL, 22.3% in LDL, and 22.3% in TC (Online Figure IV). The microbiome made a lesser, but still significant, contribution to TG (P=4x10^{-3}) and HDL (P=0.026). Our study therefore indicates that the gut microbiome can explain a substantial proportion of the variation, independent of age, gender, BMI and genetics.

Discussion

Obesity and aberrant levels of blood lipids are associated with a high risk of CVD. Studying the effect of the gut microbiome on BMI and blood lipid levels yields insight into the role of the microbiome in the development of CVD. Although animal studies have shown that microbiota can influence lipid metabolism, no large-scale studies have been performed in humans thus far. Here, we investigated the impact of the gut microbiome on BMI and blood lipid levels in 893 human subjects from the LifeLines-Deep cohort. The power of our study is reflected by three factors. First, to our knowledge, it is the largest association study linking the gut microbiome to blood lipids in humans to date. Second, our cohort represented a wide range of ages, BMI and blood lipids, as well as microbial composition. We also had detailed medication information per individual and could exclude those taking lipid-lowering or antibiotic medication. Moreover, we adopted a novel and powerful two-part model to account for both the binary and quantitative features of microbial data. We established associations for 34 taxonomies with BMI and blood lipid levels, and we estimated that gut microbiota composition can explain up to 6% of the variation in lipid levels, and that this effect is independent of age, gender and host genetics.
Our results for the microbiota associated to BMI are in line with a recent study of 416 twin-pairs from the TwinsUK population in particular, we confirmed that lower abundances of families Christensenellaceae, Rikenellaceae, class Mollicutes, genus Dehalobacterium and kingdom Archaea were associated to a high BMI. Of 22 independent taxa associated with BMI by our study, 16 were also accessed in the TwinsUK study: 11 (68.8%) showed significant association to BMI (p<0.05) with the same direction of effect as we found (Online Table V). We also identified a correlation of decreased bacterial diversity with increased BMI, which is in line with previous observations.

However, many of the taxonomies we identified are novel findings. Several of the identified bacteria are known to be involved in the bile acid metabolic pathway. In particular, order Bacteroidales (phylum Bacteroidetes) and family Clostridiaceae (phylum Firmicutes) are both negatively correlated with BMI and TG, and known to be involved in bile acid metabolism. Bile acid activity of commensal bacteria are involved in a complex interplay with host hepatic enzymes, and together they promote digestion and absorption of dietary lipids. Interestingly, several small-scale studies reported lowered cholesterol upon using probiotics with bile salt hydrolytic activity. Our study found support for the role of bacterial bile acids in lipid metabolism. Another pathway enriched in several associated bacteria is short chain fatty acids (SCFA) metabolism. Both orders Bacteroidales and Clostridiales, identified in our study, are involved in SCFA metabolism. SCFA are produced by microbiota from dietary fibers, effect host body energy homeostasis, and are protective against metabolic syndrome, type 2 diabetes, and atherosclerosis.

To firmly establish the gut microbiome as a risk factor for obesity and aberrant levels of blood lipids, we have been able to estimate that the microbiome could explain 4.57-6% of the variation in BMI, TG and HDL, respectively. We did not detect any significant association between the gut microbiome and genetic predisposition to obesity and aberrant levels of blood lipids, suggesting the variation explained by the microbiome is independent of that explained by genetic variants. It should be noted, however, that the genetic risk score was limited to our established 157 lipid-associated SNPs and 97 BMI-associated SNPs, which together only explain a small proportion of the heritability of lipid levels. We might have missed the effect of other, not yet discovered SNPs. Our risk model included age, gender, genetic variation, and gut microbiome and explained 11.3% of the variation in BMI, 17.1% in TG and 25.9% in HDL, significantly outperforming the risk model without the microbiome. Since blood lipids and BMI are highly correlated with each other and many associated bacteria were shared, we investigated whether the observed effect of the gut microbiome on lipids might just be the confounded effect of BMI. We showed that by including BMI in the risk model, the gut microbiome made a smaller, but significant, contribution to the variation in TG and HDL, suggesting that the microbiome affects blood lipids partly independently of BMI. Our results therefore indicate that the gut microbiome is a potentially important player in blood lipid metabolism. In contrast to genetics, gender and age (all fixed characteristics), an individual’s microbiota composition can be modified by diet, pre- and probiotics, and fecal transplantation. Studies have shown that diet can alter the gut microbiome. Our study has not addressed how much of the association we observed between gut microbiome and blood lipids might be explained by diet. A better understanding of this could provide more insights into the role of diet in microbiome and lipid metabolism.

Our study supports the potential of microbiota-modifying intervention to correct lipid dis-balance and thereby help prevent CVD. From potential to action, the next steps are to validate the associations we report in independent cohorts and to prove there is a causal axis of gut microbiome-lipids-CVD in functional studies. It is essential to gain more mechanistic insight into the functioning of the gut microbiome, although research in humans is still in its infancy.

The gut microbiomes in our study were profiled by 16s rRNA gene sequencing. This technology can identify microbial taxonomies and composition, but has limitations in identifying genetically-specific species and strains. Furthermore, 16s rRNA sequencing provides little
information on bacterial genes and their functions. With the decreasing cost of metagenome sequencing and development of techniques for culturing and for functional studies of gut bacteria, we expect to learn more about the levels of bacterial genes, metabolic pathways and their functions in the future.

In conclusion, we have observed a strong association between the gut microbial composition and the variation in BMI and blood lipid levels, which is independent of age, gender and host genetics. This observation provides insight into the microbiome’s role in regulating metabolic processes during the development of CVD. We established associations for a total of 34 intestinal bacteria taxonomies with BMI and blood lipids. We observed that the gut microbiome makes a significant contribution, beyond that of clinical risk factors and genetics, to the individual variance seen in BMI and to the blood levels of triglycerides and HDL, but that it has little effect on LDL or total cholesterol levels. Our results highlight the potential of therapies that alter the gut microbiome to control body mass, triglycerides and HDL in CVD prevention. In moving from potential to action, it will be essential to identify the causal axis of microbiome-lipids-CVD and to gain more mechanistic insight into the gut bacteria functions.

Methods

Population Cohort

The LifeLines-DEEP cohort is a sub-cohort of the LifeLines cohort (167,729 subjects), which employs a broad range of investigative procedures in assessing the biomedical, socio-demographic, behavioral, physical and psychological factors that contribute to the health and disease of the general population. A subset of approximately 1,500 participants also took part in LifeLines-DEEP: for these participants, additional biological materials were collected, including genome-wide genotyping and analysis of the gut microbiome composition. A full description of the LifeLines-DEEP dataset is given in the paper describing the study design.

Lipid Measurements

We had lipid measurements available for all 1,500 LifeLines-DEEP samples. Total cholesterol (TC) was measured with an enzymatic colorimetric method, high-density lipoprotein (HDL) cholesterol with a colorimetric method, and triglycerides (TG) with a colorimetric UV method (Modular P analyzer, Roche Diagnostics, Burgdorf, Switzerland). The low-density lipoprotein (LDL) cholesterol concentration was calculated using the Friedewald equation. More details were reported previously. The triglyceride level was further log$_2$ transformed.

Genotype Information

All LifeLines-DEEP samples were genotyped using the HumanCytoSNP-12 BeadChip and ImmunoChip, a customized Illumina Infinium array. The data were harmonized, merged and subsequently imputed using the Genome of the Netherlands (GoNL) dataset. Further details and information on the quality control are described in Tigchelaar et al. We removed ethnic outliers and genetically related participants from our study.

Microbiome Data Generation

Sequencing

Microbiome data was generated for 1,180 LifeLines-DEEP samples. Fecal samples were collected at home within two weeks after collection of blood samples, and stored immediately at -20°C. After transport on dry ice, all samples were stored at -80°C. Aliquots were made and DNA was isolated with the AllPrep DNA/RNA Mini Kit (Qiagen; cat. #80204). Isolated DNA was sequenced at the Broad Institute, Boston, using Illumina MiSeq paired-ends. Hyper-variable region V4 was selected using forward primer 515F [GTGCCAGCMGCCGCGGTAA] and reverse primer 806R [GGACTACHVGGGTWTCTAAT]. We used custom scripts to remove the primer sequences and align the paired-end reads. Details are given in Gevers et al.
OTU picking

Selection of unique bacterial sequences so-called operational taxonomic unit (OTU) picking was performed using the QIIME reference optimal picking, which uses UCLUST\textsuperscript{39} (version 1.2.22q) to perform the clustering. Matching OTUs to bacteria was done using a primer-specific version of the GreenGenes 13.5 reference database.\textsuperscript{40} Using TaxMan,\textsuperscript{41} we created the primer-specific reference database containing only reference entries that matched the selected primers. During this process we restricted probe-reference mismatches to a maximum of 25%. The 16S regions that were captured by our primers, including the primer sequences, were extracted from the full 16S sequences. For each of the reference sequences, we determined the overlapping part of the taxonomy of each of the reference reads in the clusters and used this overlap as the taxonomic label for the cluster. This process is based on, and similar to, work described in Bonder et al.,\textsuperscript{42} Brandt et al.,\textsuperscript{41} May et al.\textsuperscript{43} and Ding et al.\textsuperscript{44} We used QIIME\textsuperscript{45} for exploratory analysis and for gathering basic statistics on the microbiome dataset.

Quality Control

Overall, for 1,021 samples, we had lipid measurements, genotype and microbiome information. We excluded 99 samples from participants who were taking antibiotic or other potential microbiome-modifying drugs, or who were on lipid-lowering medication. The library size of microbial sequencing varied greatly among samples, ranging from 3,969 to 336,900 reads. The sequence depth can significantly bias the measures of microbial composition and rarefaction was widely used to make the library sizes equal by randomly selecting the same number of reads per sample.\textsuperscript{46,47} We compared the number of samples at different sequence depths and determined the rarefaction depth based on criteria to obtain both the number of reads and the number of samples as high as possible. We rarefied the library size to 15,000 read-depth using the \textit{rarefy} function in R package vegan (v2.3-0). At this depth, we only excluded 29 subjects. After these exclusion steps, we had 893 samples (380 males and 513 females) for final analysis. Their characteristics are summarized in Table 1.

Further, we filtered on the OTU abundance and confined our analysis to 645 OTUs, each of which comprised ≥0.05% of reads and was present in at least 1% of the population. These OTUs accounted for an average of 99% of total reads per sample. The OTUs were assigned to 173 taxonomies that were further truncated to 136 taxonomies after removing identical or highly similar information between different clade levels.

Statistical Analysis

Analysis of microbial diversity

The microbial Shannon diversity index was calculated using the \textit{diversity} function in R package vegan (version 2.3-0).

Two-part model for association analysis

We observed that the distribution of the abundance of OTUs or taxonomies departed significantly from a normal distribution due to the fact that bacteria were not presented in many samples. Only 50 out of 645 OTUs (7.7%) were presented in more than 90% of samples, whereas 448 OTUs (69.5%) were detected in less than 50% of samples. At the taxonomic level, 32 out of 136 (9.5%) taxonomies were detected in more than 90% of samples, whereas 60 taxonomies (44.1%) were detected in less than 50% of samples. There are different explanations for the detection rate: (1) the bacteria are really absent in the samples; (2) the abundance levels of bacteria are lower and not to be detected at the current sequencing and rarefaction depth; (3) the abundance levels are similar and it is a random effect due to the sequencing or rarefaction procedure. We therefore adopted a novel, two-part model that was developed to account for both binary (detected/undetected) and quantitative features.\textsuperscript{48} This approach overcomes the problem of a non-normal distribution, which is a feature of the majority of gut bacteria OTUs or taxa.
The two-part model is illustrated in Online Figure I. The first part describes a binomial analysis that tests for association of detecting a microbe (represented by an OTU or a taxonomy) with a trait. The binary feature \((b)\) of a microbe under study was coded as 0 for undetected or 1 for detected for each sample. The binary model is described as: \(y = b_1b + e\), where \(y\) refers to the trait level (BMI or lipid level) per individual after adjusting for age and gender; \(b\) is a binary feature; \(b_1\) is the estimated effect for the binary effect, and \(e\) represents the residuals.

The second part of the quantitative analysis tests for association between the lipid level and the abundance of bacteria, but only for the subjects where that microbe is present. The abundance level \((q)\) of a microbe was the log\(_{10}\) transformed read count per individual. The quantitative model is written as \(y = b_2q + e\); where \(q\) is the abundance of a microbe; \(b_2\) is the estimated effect for the abundance, and \(e\) represents the residuals.

To further combine the effect of both binary and quantitative analysis, a meta-P-value was derived using an unweighted Z method. Then a final association P value per microbe-trait pair was assigned from the minimum of P values from the binary analysis, quantitative analysis and meta-analysis. The association Z-score was calculated based on the Z-distribution. If the association direction was negative, the Z-score was assigned a negative value. If the association direction is positive, the Z-score was assigned a positive value.

The association P value was set as the minimum value of three P values and the distribution of the association P values could be skewed, so we therefore performed 1000x permutation tests to control the false discovery rate (FDR). For each permutation, we randomized the gut microbial composition across individuals and performed the two-part analysis on permuted data. At a certain P cut-off, the average number of the detected significance \((N_0)\) in 1000x permutations was defined as the false positive, and its ratio to the detected positive \((N_1)\) in the real analysis was the FDR. We controlled the FDR at 0.05.

This method accounts for the complicated features of the microbial data and maximizes the power. If the association P value comes from the binary model, indicating the effect is only due to the presence/absence of the microbe, the abundance of the microbe in the samples does not matter. If the association P value comes from the quantitative model, this indicates the abundance level of the microbe associates with the trait, and the absence of the microbe has no influence. The explanation would be another microbe takes its place and has a similar function. If the association P value comes from the meta-analysis, indicates that both the presence/absence and the abundance of microbes can influence the trait.

Estimating the Variance Explained by the Gut Microbiome

To estimate the proportion of variation in BMI and lipids that could be explained by the gut microbiome, we performed a 100x cross-validation. Each time we split the data randomly into an 80% discovery set and a 20% validation set. In the discovery set, a total of \(n\) number of significantly associated OTUs was identified at a certain P value and the effect sizes of binary and quantitative features of each OTU \((b_1\) and \(b_2\)) were estimated. Then the risk of the gut microbiome on BMI or lipids \((r_m)\) for each individual in the validation set was calculated using an additive model:

\[
r_m = \sum_{j=1}^{n} (\beta_1 + b_j + \beta_2q_j)
\]
The variation in BMI and blood lipids explained by the gut microbiome was represented as the squared correlation coefficient ($R^2$) between the traits and $r_m$, after correcting for age and gender. To ensure the robustness of our estimation, we repeated the cross-validation 100 times and calculated the average value of the explained variation. We hypothesized that many microbes may contribute a small effect but may not be confidently detected at an FDR of 0.05. Therefore, we did this analysis at different significant P levels ranging from $1 \times 10^{-5}$ to 0.1.

**Genetic Risk Score Calculation**

A total of 157 lipid-associated single nucleotide polymorphisms (SNPs)\(^2\) and 97 BMI-associated SNPs\(^2\) were extracted from the literature. The risk alleles and their effect sizes were extracted for each SNP and each lipid type. We excluded three SNPs for which genotypes could not be successfully imputed in the LifeLines cohort: rs9411489 at the ABO locus, rs3177928 at the HLA locus, and rs12016871 at the MTIF3 locus. Thus, our final study included genetic information for 96 BMI-associated SNPs and 155 lipid-associated SNPs, including 71 for HDL, 56 for LDL, 40 for TG and 72 for TC. We then computed weighted genetic risk scores ($r_g$) for BMI and lipids, as described previously.\(^3\)

The association analysis between individual SNPs and the gut microbiome was performed using the analysis pipeline developed in house for quantitative trait loci analysis.\(^4\) We further tested whether the explained variation in the gut microbiome was independent of genetic factors by testing the association between the gut microbiome and genetic risk scores.\(^5\) The associations between microbes and the genetic risk score of BMI and lipid levels were assessed using our two-part model. The significance was controlled at FDR<0.05 by 1000x permutation tests.

**The Significance of the Microbial Contribution**

To test whether the gut microbiome contributes significantly to variation in BMI and blood lipids, we compared the performance of three different risk models, in particular the risk models with and without microbial risk:

\[
\begin{align*}
    r_1 &= \text{age} + \text{gender}; \\
    r_2 &= \text{age} + \text{gender} + r_g; \quad \text{and} \\
    r_3 &= \text{age} + \text{gender} + r_g + r_m,
\end{align*}
\]

where $r_g$ is the calculated genetic risk and $r_m$ is the highest microbial risk we determined. The variation explained by each risk model was calculated in 100x cross-validation, as described above. To evaluate the significance of microbial contribution, the ANOVA test was used to compare the performance of the risk models $r_g$ and $r_m$: the average of F values of the ANOVA test from 100x cross-validation was calculated and the P value was determined based on the F-distribution. As BMI and lipids are highly correlated, we also investigated whether the gut microbiome can contribute to lipid levels independent of BMI. To do so, we tested four risk models of lipids including BMI as a risk factor:

\[
\begin{align*}
    r_1 &= \text{age} + \text{gender}; \\
    r_2 &= \text{age} + \text{gender} + \text{bmi}; \\
    r_3 &= \text{age} + \text{gender} + \text{bmi} + r_g; \quad \text{and} \\
    r_4 &= \text{age} + \text{gender} + \text{bmi} + r_g + r_m.
\end{align*}
\]
Sources of funding

This project was funded by grants from the Top Institute Food and Nutrition, Wageningen, to CW, AZ and ET (GH001), the Netherlands Organization for Scientific Research to JF (NWO-VIDI 864.13.013), CardioVasculair Onderzoek Nederland to MH and AZ (CVON 2012-03), and NWO grants to LF (ZonMW-VIDI 917.14.374) and RW (ZonMW-VIDI 016.136.308). AZ holds a Rosalind Franklin Fellowship (University of Groningen) and MCC holds a postdoctoral fellowship from the Fundación Alfonso Martín Escudero. This research received funding from the European Community’s Health Seventh Framework Programme (FP7/2007–2013, grant agreement 259867).

References

34. Li, N. et al. Pleiotropic effects of lipid genes on plasma glucose, hba1c, and homa-ir levels. Diabetes 63, 3149–3158 (2014).

Acknowledgments

We thank the LifeLines-DEEP participants and the LifeLines staff in Groningen for their collaboration. We thank Jackie Senior and Kate Mc Intyre for editing the manuscript and Mathieu Platteel for practical and analytical work.

Description of supplementary data files

The following additional data are available with the online version of this paper.

Online data:

**Online Table I** Spearman correlation between traits and OTU richness and diversity

**Online Table II** OTUs associated with BMI at FDR < 0.05 level

**Online Table III** OTUs associated with TG at FDR < 0.05 level

**Online Table IV** OTUs associated with HDL at FDR < 0.05 level

**Online Table V** Associated Taxonomies at FDR < 0.05 level.

**Online Table VI** The association between microbes and the SNPs associated with lipids and BMI at P value 1x10^-5

**Online Table VII** The associations between microbes and the combined BMI and lipid genetic risk scores at P < 0.05 level3

**Online Figure I** The workflow of the two-part model

**Online Figure II** The number of OTUs associated with TG, HDL and BMI at FDR < 0.05 and their overlaps with each other

**Online Figure III** The amount of variance in BMI and lipids explained by the gut microbiome

**Online Figure IV** The variation of lipids explained by age, gender, BMI, genetic and microbial risk.